Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response
Abstract
Both nilotinib, a second-generation tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukaemia (CML), and ponatinib, a third-generation TKI used in CML and Philadelphia positive acute lymphocytic leukaemia, have been associated with an increase in arterial occlusive events, in contrast to other TKIs such as imatinib and dasatinib. We have previously demonstrated evidence of a pro-thrombotic state associated with...
Paper Details
Title
Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response
Published Date
May 12, 2019
Journal
Volume
119
Issue
07
Pages
1112 - 1123
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History